JPMorgan Chase & Co’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $152 | Sell |
87
-16
| -16% | -$28 | ﹤0.01% | 5914 |
|
|
2025
Q1 | $139 | Sell |
103
-2
| -2% | -$3 | ﹤0.01% | 5968 |
|
|
2024
Q4 | $401 | Sell |
105
-1
| -0.9% | -$4 | ﹤0.01% | 5774 |
|
|
2024
Q3 | $286 | Hold |
106
| – | – | ﹤0.01% | 5791 |
|
|
2024
Q2 | $329 | Buy |
106
+2
| +2% | +$6 | ﹤0.01% | 5704 |
|
|
2024
Q1 | $472 | Buy |
104
+9
| +9% | +$41 | ﹤0.01% | 5712 |
|
|
2023
Q4 | $654 | Buy |
95
+2
| +2% | +$14 | ﹤0.01% | 5854 |
|
|
2023
Q3 | $584 | Buy |
93
+5
| +6% | +$31 | ﹤0.01% | 5742 |
|
|
2023
Q2 | $731 | Hold |
88
| – | – | ﹤0.01% | 5594 |
|
|
2023
Q1 | $0 | Hold |
88
| – | – | ﹤0.01% | 6084 |
|
|
2022
Q4 | $1K | Sell |
88
-175
| -67% | -$1.99K | ﹤0.01% | 5479 |
|
|
2022
Q3 | $2K | Buy |
263
+82
| +45% | +$624 | ﹤0.01% | 5345 |
|
|
2022
Q2 | $3K | Sell |
181
-319
| -64% | -$5.29K | ﹤0.01% | 5380 |
|
|
2022
Q1 | $19K | Buy |
500
+117
| +31% | +$4.45K | ﹤0.01% | 5277 |
|
|
2021
Q4 | $30K | Buy |
+383
| New | +$30K | ﹤0.01% | 5231 |
|
|
2021
Q3 | – | Sell |
-2,692
| Closed | -$269K | – | 5707 |
|
|
2021
Q2 | $269K | Hold |
2,692
| – | – | ﹤0.01% | 4346 |
|
|
2021
Q1 | $264K | Buy |
+2,692
| New | +$264K | ﹤0.01% | 4349 |
|